US equities |
NVDA $233.95 ▲+1.34% MU $1,074.89 ▼-2.05% TSLA $370.59 ▲+4.65% SPCX $158.96 ▲+7.35% SNDK $1,719.99 ▼-3.79% AMD $633.91 ▲+2.95% STX $848.99 ▼-10.21% INTC $119.33 ▼-0.56%
FinancialContent

Articles published by ARS Pharmaceuticals, Inc.

< Previous 1 2 Next >
News headline image
ARS Pharmaceuticals to Participate in Upcoming Investor Conferences
From ARS Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers SPRY
News headline image
ARS Pharmaceuticals Outlines Strategic Priorities, including a Focused Commercial Strategy, and Reports Second Quarter 2026 Financial Results
From ARS Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers SPRY
News headline image
ARS Pharmaceuticals Announces Conference Call and Webcast on August 13 Outlining its Updated Strategic Priorities and Reporting Second Quarter 2026 Financial Results
From ARS Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers SPRY
News headline image
ARS Pharmaceuticals Announces CEO Succession
From ARS Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers SPRY
News headline image
ARS Pharmaceuticals Provides Commercial and Financial Updates
From ARS Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers SPRY
News headline image
Drew Brees Collaborates with ARS Pharmaceuticals to Raise Awareness About Living Life with Severe Allergies
From ARS Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers SPRY
News headline image
ARS Pharmaceuticals Reports First Quarter 2026 Financial Results and Corporate Update
From ARS Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers SPRY
News headline image
ARS Pharmaceuticals Strengthens Leadership Team with Appointment of Industry Veteran Donn Casale as President
From ARS Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers SPRY
News headline image
ARS Pharmaceuticals Announces Conference Call and Webcast for its First Quarter 2026 Financial Results
From ARS Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers SPRY
News headline image
neffy® (epinephrine nasal spray) Approved in Canada as the First and Only Needle-Free Emergency Treatment of Allergic Reactions (anaphylaxis)
From ARS Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers SPRY
News headline image
ARS Pharmaceuticals Receives FDA Approval to Remove Age Requirement From neffy® 1 mg (epinephrine nasal spray) Label
From ARS Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers SPRY
News headline image
ARS Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Updates on neffy® (epinephrine nasal spray) Commercialization
From ARS Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers SPRY
News headline image
ARS Pharmaceuticals Announces Conference Call and Webcast for its Fourth Quarter and Full Year 2025 Financial Results and Participation at Upcoming Conferences
From ARS Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers SPRY
News headline image
ARS Pharmaceuticals to Showcase Scientific Innovation and Robust Clinical Data on neffy® (epinephrine nasal spray) at 2026 American Academy of Allergy, Asthma and Immunology (AAAAI) Annual Scientific Meeting
From ARS Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers SPRY
News headline image
EURneffy® 1 mg (adrenaline nasal spray) Recommended for Approval in the EU for Emergency Treatment of Type 1 Allergic Reactions, including Anaphylaxis in Children Weighing ≥15 kg to <30 kg
From ARS Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers SPRY
News headline image
California K-12 Schools Now Eligible for neffyinSchools Program, Offering Needle-Free Epinephrine at No Cost for Emergency Use
From ARS Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers SPRY
News headline image
neffy® (epinephrine nasal spray) Approved in China as the First and Only Community Use Epinephrine Product for the Treatment of Allergic Reactions (anaphylaxis)
From ARS Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers SPRY
News headline image
ARS Pharmaceuticals to Participate in Piper Sandler 37th Annual Healthcare Conference
From ARS Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers SPRY
News headline image
ARS Pharmaceuticals Reports Third Quarter 2025 Financial Results and Highlights for neffy® (epinephrine nasal spray)
From ARS Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers SPRY
News headline image
ARS Pharma Launches Get neffy® on Us for Patients with Severe Allergic Reactions to Improve Access to neffy (epinephrine nasal spray)
From ARS Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers SPRY
News headline image
UPDATE -- ARS Pharma to Present Real-World Data on Intranasal Epinephrine at 2025 American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting
From ARS Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers SPRY
News headline image
ARS Pharmaceuticals Announces Conference Call and Webcast for its Third Quarter 2025 Financial Results
From ARS Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers SPRY
News headline image
ARS Pharma to Present Real-World Data on Intranasal Epinephrine at 2025 American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting
From ARS Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers SPRY
News headline image
ARS Pharmaceuticals Receives Favorable Decision from European Patent Office on Patent Related to neffy® (epinephrine nasal spray)
From ARS Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers SPRY
News headline image
ARS Pharmaceuticals Secures Up to $250 Million Loan Facility with RA Capital Management and OMERS Life Sciences to Accelerate U.S. Commercialization of neffy®
From ARS Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers SPRY
News headline image
neffy® (epinephrine nasal spray) Approved in Japan as the First and Only Needle-Free Emergency Treatment of Allergic Reactions (anaphylaxis)
From ARS Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers SPRY
News headline image
Real-World Evidence Supports Clinical Effectiveness of neffy® (epinephrine nasal spray) in Patients Experiencing Anaphylaxis
From ARS Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers SPRY
News headline image
ARS Pharmaceuticals to Participate in Upcoming Investor Conferences
From ARS Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers SPRY
News headline image
ARS Pharmaceuticals Reports Second Quarter 2025 Financial Results and Highlights Accelerating Growth for neffy® (epinephrine nasal spray)
From ARS Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers SPRY
News headline image
ARS Pharmaceuticals Announces Conference Call and Webcast for its Second Quarter 2025 Financial Results
From ARS Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers SPRY
< Previous 1 2 Next >